Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Microbia Precision Engineering was a biotechnology company specializing in the development of renewable specialty ingredients and chemicals through advanced metabolic engineering and fermentation. Originally established as a division of Microbia, Inc., the company utilized a proprietary platform to rapidly optimize microbial strains for the production of high-value molecules, such as carotenoids and specialty chemicals. Its technology aimed to provide sustainable, bio-based alternatives to traditional petroleum-derived products for the food, beverage, and industrial markets. In 2010, the company was acquired by Tate & Lyle for $75 million, integrating its research and development capabilities into Tate & Lyle's global specialty food ingredients business.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Microbia Precision Engineering.